| Comprehensive analyses of tumor immunity: implications for cancer immunotherapy B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, ... Genome biology 17, 1-16, 2016 | 1903 | 2016 |
| Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma DA Braun, Y Hou, Z Bakouny, M Ficial, M Sant’Angelo, J Forman, ... Nature medicine 26 (6), 909-918, 2020 | 582 | 2020 |
| Landscape of tumor-infiltrating T cell repertoire of human cancers B Li, T Li, JC Pignon, B Wang, J Wang, SA Shukla, R Dou, Q Chen, ... Nature genetics 48 (7), 725-732, 2016 | 305 | 2016 |
| p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia JC Pignon, C Grisanzio, Y Geng, J Song, RA Shivdasani, S Signoretti Proceedings of the National Academy of Sciences 110 (20), 8105-8110, 2013 | 236 | 2013 |
| Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma DJ Kwiatkowski, TK Choueiri, AP Fay, BI Rini, AR Thorner, G De Velasco, ... Clinical Cancer Research 22 (10), 2445-2452, 2016 | 211 | 2016 |
| Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma NM Tannir, S Signoretti, TK Choueiri, DF McDermott, RJ Motzer, A Flaifel, ... Clinical Cancer Research 27 (1), 78-86, 2021 | 183 | 2021 |
| Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines JC Pignon, B Koopmansch, G Nolens, L Delacroix, D Waltregny, ... Cancer research 69 (7), 2941-2949, 2009 | 89 | 2009 |
| irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial JC Pignon, O Jegede, SA Shukla, DA Braun, CE Horak, M Wind-Rotolo, ... Clinical Cancer Research 25 (7), 2174-2184, 2019 | 88 | 2019 |
| KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1 RS Bhatt, A Berjis, JC Konge, KM Mahoney, AN Klee, SS Freeman, ... Cancer immunology research 9 (2), 156-169, 2021 | 69 | 2021 |
| Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma M Ficial, OA Jegede, M Sant'Angelo, Y Hou, A Flaifel, JC Pignon, ... Clinical Cancer Research 27 (5), 1371-1380, 2021 | 53 | 2021 |
| Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2overexpression in breast cancer cell lines G Nolens, JC Pignon, B Koopmansch, B Elmoualij, W Zorzi, E De Pauw, ... Breast Cancer Research 11, 1-11, 2009 | 32 | 2009 |
| Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression AKA Lalani, KP Gray, L Albiges, M Callea, JC Pignon, S Pal, M Gupta, ... Oncotarget 8 (61), 103428, 2017 | 22 | 2017 |
| Young investigator challenge: application of cytologic techniques to circulating tumor cell specimens: detecting activation of the oncogenic transcription factor STAT3 AC Lowe, JC Pignon, I Carvo, MG Drage, NM Constantine, N Jones, ... Cancer Cytopathology 123 (12), 696-706, 2015 | 19 | 2015 |
| ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity K Uchida, H Ross, T Lotan, JC Pignon, S Signoretti, JI Epstein, PB Illei Human pathology 46 (3), 384-389, 2015 | 18 | 2015 |
| p63+ ureteric bud tip cells are progenitors of intercalated cells SS El-Dahr, Y Li, J Liu, E Gutierrez, KS Hering-Smith, S Signoretti, ... JCI insight 2 (9), 2017 | 17 | 2017 |
| Transcriptomic correlates of tumor cell PD-L1 expression and response to nivolumab monotherapy in metastatic clear cell renal cell carcinoma T Denize, Y Hou, JC Pignon, E Walton, DJ West, GJ Freeman, DA Braun, ... Clinical Cancer Research 28 (18), 4045-4055, 2022 | 16 | 2022 |
| Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma L Hamieh, TK Choueiri, B Ogórek, D Khabibullin, D Rosebrock, D Livitz, ... PLoS genetics 14 (9), e1007679, 2018 | 15 | 2018 |
| Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell … JC Pignon, O Jegede, KM Mahoney, RB Moreira, J Novak, H Conen, ... Journal of Clinical Oncology 35 (6_suppl), 477-477, 2017 | 10 | 2017 |
| Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. M Ficial, O Jegede, M Sant'Angelo, S Moreno, DA Braun, M Wind-Rotolo, ... Journal of Clinical Oncology 38 (15_suppl), 5023-5023, 2020 | 8 | 2020 |
| Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). JC Pignon, O Jegede, SA Shukla, DA Braun, C Horak, M Wind-Rotolo, ... Journal of Clinical Oncology 37 (15_suppl), 4568-4568, 2019 | 8 | 2019 |
Sabina SignorettiProfessor, Brigham and Women's Hospital, Harvard Medical SchoolVerified email at bwh.harvard.edu
